retatrutide vs semaglutide side effects – Comparison & Benefits Retatrutide vs. semaglutide: A head-to-head

The Phase 2 trial published in the New England Journal of Medicine in 2023 reported up to 24% average weight loss at 48 weeks at the highest dose the largest number ever recorded for an obesity drug

2 Review of bariatric and metabolic surgeries Bariatric surgery remains the most effective long-term treatment for morbid obesity type-2 diabetes and metabolic syndrome, with recent updates expanding eligibility and improving safety and outcomes ( 2.1 Sleeve gastrectomy (SG) Sleeve gastrectomy (SG) is one of the most commonly performed bariatric surgical procedures aimed at inducing body mass loss and improving metabolic profile in patients with morbid obesity

Understanding this gap between promise and performance helps separate medical facts from marketing fiction

The obesity approval (Zepbound) followed in November 2023

Patients with history of pancreatitis, severe gastrointestinal disease, or who are pregnant or planning pregnancy should discuss risks with their healthcare provider